Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Total Debt (2020 - 2025)

Eton Pharmaceuticals (ETON) has disclosed Total Debt for 6 consecutive years, with $30.6 million as the latest value for Q4 2025.

  • Quarterly Total Debt rose 2.51% to $30.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $30.6 million through Dec 2025, up 2.51% year-over-year, with the annual reading at $30.6 million for FY2025, 2.51% up from the prior year.
  • Total Debt hit $30.6 million in Q4 2025 for Eton Pharmaceuticals, up from $30.4 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $30.6 million in Q4 2025 to a low of $364000.0 in Q2 2022.
  • Historically, Total Debt has averaged $8.3 million across 5 years, with a median of $1.5 million in 2023.
  • Biggest five-year swings in Total Debt: crashed 51.4% in 2022 and later soared 636.17% in 2025.
  • Year by year, Total Debt stood at $1.4 million in 2021, then decreased by 27.15% to $1.0 million in 2022, then skyrocketed by 420.81% to $5.4 million in 2023, then skyrocketed by 454.11% to $29.8 million in 2024, then grew by 2.51% to $30.6 million in 2025.
  • Business Quant data shows Total Debt for ETON at $30.6 million in Q4 2025, $30.4 million in Q3 2025, and $30.2 million in Q2 2025.